全文获取类型
收费全文 | 182篇 |
免费 | 15篇 |
国内免费 | 7篇 |
专业分类
耳鼻咽喉 | 6篇 |
儿科学 | 4篇 |
妇产科学 | 2篇 |
基础医学 | 9篇 |
口腔科学 | 4篇 |
临床医学 | 22篇 |
内科学 | 32篇 |
皮肤病学 | 10篇 |
神经病学 | 7篇 |
特种医学 | 39篇 |
外科学 | 24篇 |
综合类 | 9篇 |
预防医学 | 8篇 |
药学 | 14篇 |
肿瘤学 | 14篇 |
出版年
2023年 | 5篇 |
2020年 | 3篇 |
2019年 | 6篇 |
2017年 | 3篇 |
2016年 | 7篇 |
2015年 | 9篇 |
2014年 | 7篇 |
2013年 | 4篇 |
2012年 | 7篇 |
2011年 | 7篇 |
2010年 | 3篇 |
2009年 | 7篇 |
2008年 | 4篇 |
2007年 | 4篇 |
2006年 | 3篇 |
2005年 | 2篇 |
2004年 | 5篇 |
2003年 | 1篇 |
2002年 | 3篇 |
2001年 | 4篇 |
2000年 | 3篇 |
1999年 | 4篇 |
1998年 | 13篇 |
1997年 | 3篇 |
1996年 | 9篇 |
1995年 | 7篇 |
1994年 | 9篇 |
1993年 | 7篇 |
1991年 | 1篇 |
1990年 | 1篇 |
1989年 | 3篇 |
1988年 | 12篇 |
1987年 | 3篇 |
1986年 | 3篇 |
1985年 | 3篇 |
1984年 | 5篇 |
1983年 | 2篇 |
1982年 | 2篇 |
1981年 | 1篇 |
1980年 | 3篇 |
1979年 | 1篇 |
1978年 | 1篇 |
1977年 | 3篇 |
1976年 | 1篇 |
1975年 | 1篇 |
1970年 | 1篇 |
1968年 | 1篇 |
1958年 | 1篇 |
1955年 | 2篇 |
1944年 | 1篇 |
排序方式: 共有204条查询结果,搜索用时 15 毫秒
1.
2.
3.
4.
5.
Mutations in the LEMD3 gene were recently incriminated in Buschke–Ollendorff syndrome (BOS) and osteopoikilosis, with or without melorheostosis. The relationship of this gene with isolated sporadic melorheostosis is less clear. We investigated LEMD3 in a two-generation BOS family showing an extremely variable expression of the disease, in a sporadic patient with skin features of BOS, and in an additional subject with isolated melorheostosis. We identified two different mutations, both resulting in a premature stop codon, in the two cases of BOS. The mutation (c.2564G>A) reported in the familial case is novel, while that observed in the sporadic case (c.1963C>T) has been previously reported in an American woman with osteopoikilosis and melorheostosis who had a family history of isolated osteopoikilosis. The search for mutations in DNA extracted from the peripheral blood, as well as skin and bone biopsies of the patient with melorheostosis failed to identify any pathogenic change. Our results further expand the LEMD3 mutation repertoire, corroborate the extreme interfamilial and intrafamilial clinical variability of LEMD3 mutations, and underline the lack of a clear phenotype–genotype correlation in BOS. The present study supports the general conclusion that LEMD3 mutations do not contribute to isolated sporadic melorheostosis. The genetic or epigenetic influences that are responsible for the development of melorheostosis require further investigation. 相似文献
6.
7.
8.
BP O’Neill TM Habermann TE Witzig M Rodriguez 《Medical oncology (Northwood, London, England)》1999,16(3):211-215
Five patients at risk for primary central nervous system lymphoma (PCNSL) recurrence were treated with high-dose methylprednisolone (HDMP) to prevent 'trafficking' of malignant lymphocytes into the central nervous system (CNS). HDMP was chosen because of its ability to stabilize the 'blood brain barrier (BBB)'. Three men with newly diagnosed PCNSL, ages 62, 76 and 78y, whose survival was projected to be 6.6 months, began treatment after achieving complete response (CR) to initial radiation therapy alone and survived 27, 37 and 59 months after treatment. In none was death from recurrent disease in CNS but one patient did die of systemic non-Hodgkin's lymphoma (NHL) five years after PCNSL diagnosis. A 20 y old man was treated with HDMP after successful combined modality therapy and is alive 75+ months after initial diagnosis without evidence of disease recurrence. A 34 y old man relapsed after combined modality initial treatment and failed to respond to HDMP when treatment was begun after unsuccessful salvage therapy; he died of disease 12 months after initial diagnosis. There were no treatment complications. The promising results in this pilot study from the basis for a North Central Cancer Treatment Group (NCCTG) 96-73-51, a Phase 2 clinical trial of brain radiotherapy and HDMP for PCNSL patients 70y of age and older, a group of patients at high risk for toxicity from intensive combined modality therapy. 相似文献
9.
Oscillatory motion of the normal cervical spinal cord 总被引:2,自引:0,他引:2
10.
J Termote NE Schalij-Delfos BP Cats D Wittebol-Post BR Hoogervorst HAA Brouwers 《Acta paediatrica (Oslo, Norway : 1992)》1996,85(12):1491-1496
To assess the effect of surfactant replacement therapy (SRT) on the prevalence and severity of retinopathy of prematurity (ROP), we compared data from 160 SRT-treated preterm infants with data from 230 historic controls. The prevalence of ROP was 30.6% in the treatment group and 23.4% in the control group. Severe ROP (stages 3-4) was seen in 6.1% of the infants with ROP in the treatment group and 20.3% of the ROP patients in the control group. Surfactant therapy had no influence on the prevalence of ROP (odds ratio 1.4, 95% confidence interval 0.797-2.459, p = 0.242). However, SRT was associated with a decreased risk for severe ROP, compared to mild ROP (odds ratio 0.226, 95% confidence interval 0.056-0.905, p = 0.036). These data suggest that SRT is associated with a decreased risk for severe ROP. 相似文献